Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

The role of nonrandomized trials in the evaluation of oncology drugs

(2015) R Simon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state

(2014) Mads Emil Bjørn et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α

(2014) Caroline H. Riley et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

(2014) C. Nielsen et al.   HAEMATOLOGICA

Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials

(2014) J. Mascarenhas et al.   HAEMATOLOGICA

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation

(2014) Bin-Tao Huang et al.   LEUKEMIA RESEARCH

The platelet–cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?

(2014) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

(2014) Bruno Cassinat et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression

(2014) Hans Carl Hasselbalch et al.   PLoS One

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms

(2014) Hans C Hasselbalch   Expert Review of Hematology

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

(2013) Jean-Christophe Ianotto et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of cytokines in the initiation and progression of myelofibrosis

(2013) Hans C. Hasselbalch   CYTOKINE & GROWTH FACTOR REVIEWS

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

(2013) T Barbui et al.   LEUKEMIA

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

(2013) A Tefferi et al.   LEUKEMIA

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression

(2013) C Marty et al.   LEUKEMIA

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

(2013) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

(2013) Thomas Stauffer Larsen et al.   LEUKEMIA RESEARCH

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

(2013) Richard T Silver et al.   Expert Review of Hematology

Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis

(2012) Rakhee Vaidya et al.   AMERICAN JOURNAL OF HEMATOLOGY

Diagnostic value ofJAK2V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population

(2012) Camilla Nielsen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

(2012) Hans Carl Hasselbalch et al.   CURRENT DRUG TARGETS

Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis

(2012) Tomer Avni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis

(2012) Vibe Skov et al.   EXPERIMENTAL HEMATOLOGY

Experience with pegylated interferon  -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

(2012) K. Gowin et al.   HAEMATOLOGICA

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

(2012) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

The Role of Iron in Learning and Memory

(2012) Stephanie J. B. Fretham et al.   Advances in Nutrition

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study

(2011) H. Frederiksen et al.   BLOOD

Recombinant interferon-  may retard progression of early primary myelofibrosis: a preliminary report

(2011) R. T. Silver et al.   BLOOD

The renaissance of interferon therapy for the treatment of myeloid malignancies

(2011) J.-J. Kiladjian et al.   BLOOD

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- 

(2011) C. H. Riley et al.   BLOOD

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

(2011) Roberto Latagliata et al.   CANCER

Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders

(2011) Jerry L Spivak et al.   Expert Review of Anticancer Therapy

Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms

(2011) Hans Carl Hasselbalch et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

(2011) Jean-Jacques Kiladjian et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

(2011) M Nakatake et al.   ONCOGENE

Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling

(2010) Edwin Chen et al.   CANCER CELL

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

(2010) T. Barbui et al.   HAEMATOLOGICA

Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells

(2010) J-J Kiladjian et al.   LEUKEMIA

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

(2009) Thomas Stauffer Larsen et al.   Hematology

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

(2008) T. S. Larsen et al.   ANNALS OF HEMATOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders

(2008) I. Plo et al.   BLOOD

Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer

(2008) Hans Carl Hasselbalch   LEUKEMIA RESEARCH